TTrialPathMatch Me to Trials
← Back to trials
RecruitingPIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular Malformations

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

Eligible age

2+ yrs

Accepts

All genders

Locations

19 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.

Sponsor: Relay Therapeutics, Inc.

Where it's recruiting

Arizona

Phoenix

Arkansas

Little Rock

California

Los Angeles · Palo Alto · San Francisco

Colorado

Aurora

Georgia

Atlanta

Indiana

Indianapolis

Iowa

Iowa City

Maryland

Baltimore

Michigan

Grand Rapids

Minnesota

Rochester

Missouri

Columbia · St Louis

Source: ClinicalTrials.gov · NCT06789913 · last updated 2026-11-19

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adul · TrialPath